Loading organizations...
§ Private Profile · Toronto, Canada
Medical device company developing neuromodulation technologies for patients with pelvic health disorders and other neuromodulation applications.
EBT Medical is a clinical-stage medical device company operating in an undisclosed location that develops advanced neuromodulation technologies and peripheral nerve stimulation therapies for various complex health conditions. The organization focuses heavily on algorithm-based neurostimulation innovations, primarily centering its current product development pipeline around the proprietary NiNA device. These specialized clinical solutions are specifically designed to treat and manage patients suffering from overactive bladder, severe pelvic health disorders, urinary dysfunction, obstructive sleep apnea, and chronic heart failure. The executive management team brings extensive medical technology industry experience from major global healthcare corporations, including recognizable corporate entities such as Medtronic, Boston Scientific, AMS, and Cogentix. While the exact founding year remains currently undisclosed in public financial records, EBT Medical was officially established by the collaborative efforts of co-founders Paul Yoo, Mr. Carlton, and Dr. John.
EBT Medical has raised $10.0M across 1 funding round.
EBT Medical has raised $10.0M in total across 1 funding round.
EBT Medical is a clinical-stage medical device company developing noninvasive neuromodulation technologies to treat pelvic health disorders, starting with overactive bladder (OAB).[1][2][3][4] Its flagship product is a discreet, clinical-grade neurostimulator and ecosystem targeting the saphenous nerve, serving patients with OAB by offering a novel alternative to traditional therapies.[1][4] The company, spun out of the University of Toronto, reports 2024 revenue of $200,000 with around 6-12 employees, backed by investors like SV Health Investors and Genesys Capital, and demonstrates growth through a significant patent estate and experienced leadership in neuromodulation and pelvic health.[1][4]
EBT Medical was founded in 2014 in Toronto, Ontario, based on the discovery of the saphenous nerve's role in modulating pelvic health function, enabling new treatment approaches for disorders like OAB.[1][4] Co-Founder and Chief Scientific Officer Paul Yoo leads a management team and advisory board with decades of experience in pelvic health, neuromodulation, and consumer health; the company emerged from University of Toronto entrepreneurship programs as a venture-backed entity.[1][2][3][4] Early traction includes building a patent portfolio around saphenous nerve neuromodulation for pelvic indications and advancing to clinical-stage development of its first product.[1][4]
EBT Medical rides the neuromodulation wave in medtech, targeting the growing pelvic health market where OAB affects millions and current treatments like drugs or implants have limitations in efficacy and invasiveness.[1][2][4] Timing aligns with advances in noninvasive neurostimulation and rising demand for patient-friendly alternatives amid aging populations and post-pandemic health tech focus. Market forces favoring it include patent protection, university spinout momentum, and investor interest in medtech with real-world traction, positioning EBT to influence pelvic disorder care by shifting paradigms toward nerve-specific, accessible therapies.[1][4]
EBT Medical's path forward involves regulatory milestones, commercialization of its OAB neurostimulator, and expansion to other pelvic indications via its saphenous nerve platform.[1][4] Trends like miniaturized neuromodulation, AI-enhanced personalization, and value-based care will accelerate adoption, potentially scaling revenue beyond $200K as clinical data builds. Its influence may grow by pioneering noninvasive standards in pelvic health, returning to its founding mission of reimagining treatments from Toronto's innovation hub.[1][2][4]
EBT Medical has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in November 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2019 | $10M Series A | Genesys Capital, Greg Madden | SV Health Investors | Announced |
EBT Medical has raised $10.0M in total across 1 funding round.
EBT Medical's investors include Genesys Capital, Greg Madden, SV Health Investors.